Detail akcie Selvita online

Business Summary: Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Ryvu Therapeutics SA revenues decreased 22% to PLN16.9M. Net loss increased 30% to PLN25.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Innovative segment loss increase of 68% to PLN37.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -PLN0.84 to -PLN1.09.